CN102627614B - Diquinazoline diselenide compound as well as preparation method and bioactivity thereof - Google Patents
Diquinazoline diselenide compound as well as preparation method and bioactivity thereof Download PDFInfo
- Publication number
- CN102627614B CN102627614B CN201210086997.8A CN201210086997A CN102627614B CN 102627614 B CN102627614 B CN 102627614B CN 201210086997 A CN201210086997 A CN 201210086997A CN 102627614 B CN102627614 B CN 102627614B
- Authority
- CN
- China
- Prior art keywords
- diselenide
- bis
- compound
- general formula
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 diselenide compound Chemical class 0.000 title claims abstract description 73
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- JSJQXIKNYJDACT-UHFFFAOYSA-N (potassiodiselanyl)potassium Chemical compound [Se-][Se-].[K+].[K+] JSJQXIKNYJDACT-UHFFFAOYSA-N 0.000 claims abstract description 6
- MQUNPMBEKMVOHA-UHFFFAOYSA-N (sodiodiselanyl)sodium Chemical compound [Na][Se][Se][Na] MQUNPMBEKMVOHA-UHFFFAOYSA-N 0.000 claims abstract description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 6
- GUPDYNLFBASSJR-UHFFFAOYSA-N [Li][Se][Se][Li] Chemical compound [Li][Se][Se][Li] GUPDYNLFBASSJR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 18
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 239000013078 crystal Substances 0.000 claims description 16
- 229940041181 antineoplastic drug Drugs 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical class C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 claims description 4
- YFQWRWDALHRGHA-UHFFFAOYSA-N 6,8-dibromo-4-[(6,8-dibromoquinazolin-4-yl)diselanyl]quinazoline Chemical compound C1=C(Br)C=C2C([Se][Se]C3=NC=NC4=C(Br)C=C(C=C43)Br)=NC=NC2=C1Br YFQWRWDALHRGHA-UHFFFAOYSA-N 0.000 claims description 4
- ZKTGTNOTYKYDFB-UHFFFAOYSA-N 6-chloro-4-[(6-chloroquinazolin-4-yl)diselanyl]quinazoline Chemical compound C1=C(Cl)C=C2C([Se][Se]C3=NC=NC4=CC=C(C=C43)Cl)=NC=NC2=C1 ZKTGTNOTYKYDFB-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- PRCBMWLUWBOSRX-UHFFFAOYSA-N 2,6-dichloro-4-[(2,6-dichloroquinazolin-4-yl)diselanyl]quinazoline Chemical compound C1=C(Cl)C=C2C([Se][Se]C3=NC(Cl)=NC4=CC=C(C=C43)Cl)=NC(Cl)=NC2=C1 PRCBMWLUWBOSRX-UHFFFAOYSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 230000001093 anti-cancer Effects 0.000 abstract description 7
- 206010006187 Breast cancer Diseases 0.000 abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 35
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 229910052711 selenium Inorganic materials 0.000 description 15
- 239000011669 selenium Substances 0.000 description 15
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 14
- 238000002844 melting Methods 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 11
- LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 150000003246 quinazolines Chemical class 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940065287 selenium compound Drugs 0.000 description 3
- 150000003343 selenium compounds Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000724252 Cucumber mosaic virus Species 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229950010033 ebselen Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- DGHKCBSVAZXEPP-UHFFFAOYSA-N 2,4-dichloro-6,7-dimethoxyquinazoline Chemical compound ClC1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 DGHKCBSVAZXEPP-UHFFFAOYSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N 2-amino-4-methylselanyl-butanoic acid Chemical compound C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- OXWAQRCVLUTMKY-UHFFFAOYSA-N 4,6,8-trichloroquinazoline Chemical compound N1=CN=C(Cl)C2=CC(Cl)=CC(Cl)=C21 OXWAQRCVLUTMKY-UHFFFAOYSA-N 0.000 description 1
- RKICQFNPYTWKSN-UHFFFAOYSA-N 4,6-dichloro-2-methylquinazoline Chemical compound C1=C(Cl)C=CC2=NC(C)=NC(Cl)=C21 RKICQFNPYTWKSN-UHFFFAOYSA-N 0.000 description 1
- JEBCOVKUVLFOGR-UHFFFAOYSA-N 4,6-dichloroquinazoline Chemical compound N1=CN=C(Cl)C2=CC(Cl)=CC=C21 JEBCOVKUVLFOGR-UHFFFAOYSA-N 0.000 description 1
- XEZNRGUAWYQLIT-UHFFFAOYSA-N 4-chloro-6,7-diethoxy-2-methylquinazoline Chemical compound CC1=NC(Cl)=C2C=C(OCC)C(OCC)=CC2=N1 XEZNRGUAWYQLIT-UHFFFAOYSA-N 0.000 description 1
- HGMQPDNSSYTATF-UHFFFAOYSA-N 4-chloro-6,7-diethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OCC)C(OCC)=CC2=N1 HGMQPDNSSYTATF-UHFFFAOYSA-N 0.000 description 1
- VHTOWTBCVHATEY-UHFFFAOYSA-N 4-chloro-6,7-dimethoxy-2-methylquinazoline Chemical compound CC1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 VHTOWTBCVHATEY-UHFFFAOYSA-N 0.000 description 1
- PUGXZUHUYQNRIF-UHFFFAOYSA-N 6,8-dibromo-4-chloroquinazoline Chemical compound C1=C(Br)C=C2C(Cl)=NC=NC2=C1Br PUGXZUHUYQNRIF-UHFFFAOYSA-N 0.000 description 1
- JFJNDMNYNYLFLJ-UHFFFAOYSA-N 6-bromo-4-chloroquinazoline Chemical compound C1=C(Br)C=C2C(Cl)=NC=NC2=C1 JFJNDMNYNYLFLJ-UHFFFAOYSA-N 0.000 description 1
- MRGAYLMLXNPVGO-UHFFFAOYSA-N CC1=NC2=C(C=C(C=C2C(=N1)Cl)Cl)Cl Chemical compound CC1=NC2=C(C=C(C=C2C(=N1)Cl)Cl)Cl MRGAYLMLXNPVGO-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical class C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- LEQRFHXXXRSFLO-UHFFFAOYSA-N [N].[Se] Chemical compound [N].[Se] LEQRFHXXXRSFLO-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000000005 bacterial plant pathogen Species 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940043231 innovative antineoplastic drug Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an anti-tumor drug-diquinazoline diselenide compound as well as a preparation method and bioactivity thereof, which are the compound represented by the following general formula and the preparation method thereof. In the general formula, R1, R2, R3, R4 and R5 are as defined in the specification. The invention introduces the anti-tumor drug-diquinazoline diselenide compound prepared by the steps of with 4-chlorinated quinazoline and sodium diselenide or potassium diselenide or lithium diselenide as raw materials and water, ethanol, isopropanol, absolute ethanol, N,N-dimethyl formamide, dioxane, dimethyl sulfoxide or a mixture thereof as a solvent, reacting and synthesizing. The compounds a, h have proliferation inhibition effects on breast cancer cells MDA-MB-435 and have good anti-cancer activity.
Description
Technical Field
The invention belongs to organic selenium nitrogen heterocyclic quinazoline drugs, and particularly relates to an antitumor drug bisquinazoline diselenide compound, and a preparation method and biological activity thereof.
Background
In recent years, a great deal of research data show that quinazoline compounds show good biological activity, and especially have prominent effect on inhibiting EGF receptor and tyrosine kinase phosphorylation thereof. There are a large number of documents, patents, articles, etc. reported each year. In the aspect of medicine, for example, commercial Iressa (ZD 1839), Tarceva (OSI-774), PD153035, PD16941 and the like have an inhibitory effect on EGFR, and further show an anti-cancer activity, and also have antimalarial, anti-tumor and anti-HIV activities. Quinazoline small molecular compound energyThe tyrosine kinase inhibitor can be combined with EGFR with high selectivity and is strong, and clinical researches show that the tyrosine kinase inhibitor can lead cells to stay at G1And (4) period. In the aspect of pesticides, in particular to quinazoline oxime ether compounds with the activity of resisting Tobacco Mosaic Virus (TMV), Cucumber Mosaic Virus (CMV) and other plant pathogenic bacteria. Quinazoline compounds possess such a wide range of biological activities that they have generated great interest to medical researchers and chemists. In order to find the site of action of quinazoline Compounds, Lim et al (Lim, J. K.; Negash, K.; Hanraham, S. M.; Van Brocklin, H.F. Journal of laboratory Compounds and Radiopharmaceuticals, 2000, 43, 1183-1191) synthesized two bands [ I153035 ] using two different methods as lead Compounds125]The IC of the target compound for EGFR-TK is determined by measuring the purity of the radiolabeled quinazoline compound by HPLC with a spectrophotometer detector500.025 and 0.006 nmol/L respectively, and the activity of inhibiting EGFR is better than PD 153035; the radioactivity is measured, and the action site is found by radioactive tracing measurement. 7-substituted 1, 4-EGF receptor tyrosine kinase inhibitors were reported by Lee et al (Lee, J. Y.; Park, Y. K.; Seo, S. H.; Yang, B. S.; Park, H.; Lee, Y.S. Arch. pharm. Pharm. Med. chem. 2002, 335 (10), 487-494.) in 2002]Dioxane [2, 3-g ]]The quinazoline compound has the activity superior to or close to that of PD153035 through biological tests of EGF receptor tyrosine kinase of A431 cells, HCT116 cells and SUN638 cells. In 2006 Ballard et al (Ballard P, Bradbury R H, Harris C S, et al, bioorg. Med. chem. Lett., 2006, 16 (6), 1633-1637) designed and synthesized a novel class of 4-arylamino quinazoline compounds with inhibitory activity against EGFR, and part of IC of the target compounds50Below 2 nmol/L. In 2007, Wissner et al (Wissner A, Fraser H L, Ingalils C L, et al, bioorg. Med. chem., 2007, 15 (11), 3635-one 3648) report that a novel 4-quinonamine quinazoline compound shows good inhibitory effect on EGFR, and IC of part of target compounds50Can reach 2.6 nmol/L. Gong et al (Gong G, Xie Y, Liu Y, et al, bioorg. Med. chem. Lett., 2009, 19 (4), 1191-Bu 1194) reported a class of 2-thiophene extractionsThe substituted-4-hydrazino substituted quinazoline compounds can promote the conduction activity of NF-kB, which is different from the currently found quinazoline compounds that can block the conduction activity of NF-kB.
Selenium is a trace element necessary for human bodies, is a constituent component of various enzymes, and has the functions of resisting diseases, delaying senility and enhancing the immunity of the organisms in the human bodies, thereby achieving the effect of balancing the environment in the organisms. Selenium has wide biological functions, is an important component of erythrocyte glutathione peroxidase, can participate in the synthesis of coenzyme A and coenzyme Q, is a protective agent for resisting toxic substances in vivo, can promote lymphocytes to generate antibodies, and is also an inducer for promoting the gene regulation and normalization of canceration early-stage disorder. Since the last 70 th generation of scientists discovered selenium to have antitumor effects, subsequent studies demonstrated that selenium is a potent inhibitor of breast, liver, skin, colon and stomach cancers and the like (Wei W Q, Abnet C, Qiao Y L, et al Am. J. Clin. Nutr., 2004, 79 (1), 80-85; Kellen E, Zeegers M, Buntinx F. int. J. Urol., 2006, 13 (9), 11802-11804; Wu X-W, Yu Z-K. Tetrahedron Lett., 2010, 51 (11), 1500-1503). The selenium compound has anticancer effect via multiple mechanisms and multiple targets, and compared with inorganic selenium, the organic selenium has the features of high bioavailability, high bioactivity, low toxicity, less environmental pollution, etc. In recent years, organic selenium compounds such as selenium chitosan selenide, selenium-containing protein, selenium polysaccharide, selenium methionine, selenium carrageenan, selenium tea polyphenol and other selenium micromolecular or biological macromolecule compounds are obviously higher than those of corresponding compounds which are not selenylated in terms of biological activities such as tumor resistance, cardiovascular disease treatment, aging resistance, organism immunity improvement and the like. Representative drugs currently under clinical investigation, such as Ebselen (Ebselen) as an anti-inflammatory and anti-oxidant drug (Schewe T. Gen. Pharmacol-Vasc. S., 1995, 26 (6), 1153-1169; Azad G K, Balsterihna S J, Sathish N, et al biochem. Pharmacol., 2012, 83 (2), and-. The development of new therapeutic drugs using the unique chemical and biological properties of selenium has attracted increasing attention of scientists, and the synthesis of organic selenium compounds with high biological activity and low toxicity remains a major hotspot of current drug research (Ninomiya M, Garud D R, Koketsu M, et al coordin. chem. rev., 2011, 255 (23-24), 2968-2990; plato D, Ib a ñ ez E, Palop J a, et al struct. chem., 2011, 22 (6), 1233-1240; Terazawa R, Garud D R, Hamada N, bio-org. chem., 2010, 18 (19), 7001 med 7008; Bijian K, Zhang Z-W, Xu B, et al. eur. chem. J. 152, 48, 143-143).
In conclusion, with the design and synthesis of the organic metal anticancer compound and the discovery of the action target of a new medicament, a theoretical basis is laid for medicinal chemists to develop innovative medicaments with independent intellectual property rights; with the research of quinazoline compounds in recent years, a plurality of series of novel quinazoline compounds are designed and synthesized, wherein good EGFR inhibitory activity is not shown, and the quinazoline compounds have further research value. Based on the multiple denaturation of a substituent at the 4-position of a quinazoline ring and the multi-mechanism and multi-target anticancer effect of a selenium-containing compound, a new diquinazoline diselenide compound is synthesized, and an innovative anticancer drug with independent intellectual property rights is developed.
Disclosure of Invention
An anti-tumor drug, which is characterized in that the drug is a bis-quinazoline diselenide compound represented by the following general formula (I):
(I)
wherein,
R1、R2、R3、R4and R5Each is hydrogen, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group; but does not include R1、R2、R3、R4And R5Are all hydrogen.
The anti-tumor drug has the general formula (I) shown in the specification, wherein R is1、R4And R5Are each hydrogen, R2And R3Selected from C1-6 alkyl and C1-6 alkoxy.
In the context of the present invention, the C1-6 alkyl group may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, neopentyl, n-hexyl, isohexyl, tert-hexyl, neohexyl.
In the context of the present invention, C1-6 alkoxy may be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, isopentoxy, tert-pentoxy, neopentoxy.
The anti-tumor drug has the general formula (I) shown in the specification, wherein R is1、R3And R5Are each hydrogen, R2And R4Selected from halogen atoms.
In the context of the present invention, the halogen atom may be a fluorine, chlorine, bromine or iodine atom.
The anti-tumor drug has the general formula (I) shown in the specification, wherein R is5Is methyl, R1、R2、R3And R4Selected from halogen atom, C1-6 alkyl, C1-6 alkoxy; in particular R1And R4Is hydrogen, R2And R3Selected from methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, isopentoxy, tert-pentoxy, neopentoxy.
The anti-tumor drug is characterized in that the partially synthesized compound is as follows:
a.1, 2-bis (6, 7-dimethoxyquinazolin-4-yl) diselenide,
b.1, 2-bis (6, 7-diethoxyquinazolin-4-yl) diselenide,
c.1, 2-bis (2-methyl-6, 7-dimethoxyquinazolin-4-yl) diselenide,
d.1, 2-bis (2-methyl-6, 7-diethoxyquinazolin-4-yl) diselenide,
e.1, 2-bis (2-chloro-6, 7-dimethoxyquinazolin-4-yl) diselenide,
f.1, 2-bis (2-chloro-6, 7-diethoxyquinazolin-4-yl) diselenide,
g.1, 2-bis (6-chloroquinazolin-4-yl) diselenide,
h.1, 2-bis (6, 8-dichloroquinazolin-4-yl) diselenide,
i.1, 2-bis (2-methyl-6-chloroquinazolin-4-yl) diselenide,
j.1, 2-bis (2-methyl-6, 8-dichloroquinazolin-4-yl) diselenide,
k.1, 2-bis (2-chloro-6-chloroquinazolin-4-yl) diselenide,
1, 2-bis (2-chloro-6, 8-dichloroquinazolin-4-yl) diselenide,
m, 1, 2-bis (6-bromoquinazolin-4-yl) diselenide,
n, 1, 2-bis (6, 8-dibromoquinazolin-4-yl) diselenide,
o, 1, 2-bis (2-methyl-6-bromoquinazolin-4-yl) diselenide,
p, 1, 2-bis (2-methyl-6, 8-dibromoquinazolin-4-yl) diselenide,
q, 1, 2-bis (2-chloro-6-bromoquinazolin-4-yl) diselenide,
r.1, 2-bis (2-chloro-6, 8-dibromoquinazolin-4-yl) diselenide.
The above-mentioned one for antitumor drugThe preparation method is characterized in that 4-chloroquinazoline, sodium diselenide or potassium diselenide or lithium diselenide are taken as raw materials, and water, ethanol, isopropanol, absolute ethanol, sodium diselenide, potassium diselenide, lithium diselenide, sodium diselen,N,N-dimethylformamide, dioxane, dimethylsulfoxide or a mixture thereof as a solvent, and reacting to synthesize: adding 4-chloroquinazoline in batches at 20-120 ℃ into the prepared solution of sodium diselenide, potassium diselenide or lithium diselenide, performing reflux reaction for 3-36h, cooling, performing suction filtration to obtain a brownish red solid, and using the brownish red solidN,NRecrystallizing dimethyl formamide and water to obtain orange to brownish red crystals, namely the product of the bis-quinazoline diselenide compound. The synthetic chemical reaction equation is as follows:
the method is suitable for synthesizing all the above bis-quinazoline diselenide compounds.
The anti-tumor drug can be a pharmaceutical composition, and is characterized by comprising an effective amount of a compound shown in formula (I) or a pharmaceutically acceptable salt thereof, and the application of the anti-tumor drug is to treat and prevent various benign or malignant tumors, wherein the tumors comprise prostate cancer, leukemia, skin cancer, gastric cancer, breast cancer, liver cancer, lung cancer, ovarian cancer, cervical cancer, lymph cancer, colorectal cancer, nasopharyngeal cancer and oral cancer, and particularly the prostate cancer and the breast cancer.
The pharmaceutical compositions comprise as active ingredient at least a compound of formula (I) as such or in admixture with one or more pharmaceutically acceptable inert non-toxic excipients or carriers.
Detailed Description
The following examples will better illustrate the invention, but it should be emphasized that the invention is in no way limited to what is shown in these examples.
The following examples show different aspects of the invention, and the data given include specific operating and reaction conditions and products whose purity confirms their structure by infrared spectroscopy, nuclear magnetic resonance hydrogen spectroscopy and mass spectrometry.
Example 1, Synthesis of 1, 2-bis (6, 7-dimethoxyquinazolin-4-yl) diselenide (compound No. a).
0.3 g (3.8 mmol) of selenium, 0.1 g (2.6 mmol) of sodium borohydride and 15 mL of absolute ethyl alcohol are sequentially added into a 150 mL three-necked bottle provided with a reflux condenser tube, the temperature of an ice water bath is controlled to be below 3 ℃, the solution turns brown from black, the solution turns reddish brown after about 10min, the ice bath is removed, and the solution is heated, stirred and refluxed for 1.5 h and turns dark brown. Adding 2.5 mmol 6, 7-dimethoxy-4-chloroquinazoline in batches, adding for about 1 h, changing the solution into dark brick red, refluxing for 24h, cooling to room temperature, adjusting the pH of the reaction system to =5-6 with glacial acetic acid, performing desolventization under reduced pressure to obtain an earthy yellow solid, and recrystallizing with DMF and water (V)DMF/H2O= 5: 1) to obtain orange crystal, namely the product 1, 2-bis (6, 7-dimethoxyquinazoline-4-yl) diselenide, the yield is 53.8 percent, and the melting point is>300℃。IR (KBr) v: 3039.6 (vAr-H), 2945.3 (v as CH3), 2845.0 (v s CH3), 1602.9-1467.8 (quinazoline skeleton vibration), 1246.0 (v as Ar-O-C), 1136.1 (v s Ar-O-C), 786.9 (δAr-H) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 8.93 (s, 2H, quinazoline H-2), 7.60 (s, 2H, quinazoline H-8), 7.29 (s, 2H, quinazoline H-5), 4.06, 4.01 (2s, 12H, 4OCH3). EIMS: m/z 538 (M+ ·, 17.2)。
Example 2 synthesis of 1, 2-bis (6, 7-diethoxyquinazolin-4-yl) diselenide (compound No. b).
Synthesized according to the method and conditions of example 1, except for 6, 7-dimethoxyThe base-4-chloroquinazoline is replaced by 6, 7-diethoxy-4-chloroquinazoline to obtain the product 1, 2-bis (6, 7-diethoxy-quinazolin-4-yl) diselenide which is orange crystal, the yield is 52.6 percent, and the melting point is high>300℃。IR (KBr) v: 3036.9 (vAr-H), 2946.7 (v as CH3), 2935.8 (v as CH2), 2847.4 (v s CH3), 2836.4 (v s CH2), 1608.2-1464.6 (quinazoline skeleton vibration), 1242.6 (v as Ar-O-C), 1134.8 (v s Ar-O-C), 787.6 (δAr-H) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 8.95 (s, 2H, quinazoline H-2), 7.64 (s, 2H, quinazoline H-8), 7.31 (s, 2H, quinazoline H-5), 4.09, 4.06 (2s, 8H, 4OCH2), 1.34, 1.31 (2s, 12H, 4CH3). EIMS: m/z 594 (M+ ·, 18.6)。
Example 3 synthesis of 1, 2-bis (2-methyl-6, 7-dimethoxyquinazolin-4-yl) diselenide (compound No. c).
Synthesis by the method and conditions of example 1, substituting only 6, 7-dimethoxy-4-chloroquinazoline for 2-methyl-6, 7-dimethoxy-4-chloroquinazoline gave the product 1, 2-bis (2-methyl-6, 7-dimethoxyquinazolin-4-yl) diselenide as an orange yellow crystal, 48.2% yield, melting point>300℃。IR (KBr) v: 3030.2 (vAr-H), 2954.2 (v as CH3), 2865.9 (v s CH3), 1614.8-1458.2 (quinazoline skeleton vibration), 1248.3 (v as Ar-O-C), 1139.4 (v s Ar-O-C), 779.8 (δAr-H) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 7.63 (s, 2H, quinazoline H-8), 7.39 (s, 2H, quinazoline H-5), 3.90, 3.85 (2s, 12H, 4OCH3), 2.46, 2.42 (2s, 6H, 2CH3). EIMS: m/z 566 (M+ ·, 15.2)。
Example 4 synthesis of 1, 2-bis (2-methyl-6, 7-diethoxyquinazolin-4-yl) diselenide (compound No. d).
Synthesized as in example 1, except for changing 6, 7-dimethoxy-4-chloroquinazoline to 2-methyl-6, 7-diethoxy-4-chloroquinazoline, the product 1, 2-bis (2-methyl-6, 7-diethoxyquinazolin-4-yl) diselenide was obtained as orange yellow crystals in 45.6% yield and melting point>300℃。IR (KBr) v: 3033.0 (vAr-H), 2956.3 (v as CH3), 2948.5 (v as CH2), 2869.7 (v s CH3), 2838.6 (v s CH2), 1618.8-1451.7 (quinazoline skeleton vibration), 1247.8 (v as Ar-O-C), 1132.4 (v s Ar-O-C), 781.7 (δAr-H) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 7.65 (s, 2H, quinazoline H-8), 7.41 (s, 2H, quinazoline H-5), 4.05, 4.02 (2s, 8H, 4OCH2), 2.47, 2.45 (2s, 6H, 2CH3), 1.36, 1.33 (2s, 12H, 4CH3). EIMS: m/z 622 (M+ ·, 13.7)。
Example 5 Synthesis of 1, 2-bis (2-chloro-6, 7-dimethoxyquinazolin-4-yl) diselenide (compound No. e).
Synthesized as in example 1, substituting only 6, 7-dimethoxy-4-chloroquinazoline for 6, 7-dimethoxy-2, 4-dichloroquinazoline, provided the product 1, 2-bis (2-chloro-6, 7-dimethoxyquinazolin-4-yl) diselenide as an orange-red crystal, 53.8% yield, melting point>300℃。IR (KBr) v: 3032.1 (vAr-H), 2958.1 (v as CH3), 2868.5 (v s CH3), 1618.2-1460.8 (quinazoline skeleton vibration), 1250.4 (v as Ar-O-C), 1140.6 (v s Ar-O-C), 787.1 (δAr-H) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 7.67 (s, 2H, quinazoline H-8), 7.43 (s, 2H, quinazoline H-5), 3.99, 3.89 (2s, 12H, 4OCH3). EIMS: m/z 606 (M+ ·, 28.5)。
Example 6 Synthesis of 1, 2-bis (6-chloroquinazolin-4-yl) diselenide (compound No. g).
Synthesized as in example 1, except for the change of 6, 7-dimethoxy-4-chloroquinazoline to 4, 6-dichloroquinazoline, to give the product 1, 2-bis (6-chloroquinazolin-4-yl) diselenide as an orange yellow crystal, 50.3% yield, melting point>300℃。IR (KBr) v: 3039.9 (vAr-H), 1496.4-1570.1 (quinazoline skeleton vibration) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 8.75 (s, 2H, quinazoline H-2), 8.31 (s, 2H, quinazoline H-5), 7.86 (d, J = 8.8 Hz, 2H, quinazoline H-8), 7.73 (d, J = 8.8 Hz, 2H, quinazoline H-7). EIMS: m/z 484 (M+ ·, 20.8)。
Example 7 synthesis of 1, 2-bis (6, 8-dichloroquinazolin-4-yl) diselenide (compound No. h).
Synthesized as in example 1, except for changing 6, 7-dimethoxy-4-chloroquinazoline to 4,6, 8-trichloroquinazoline, to give the product 1, 2-bis (6, 8-dichloroquinazolin-4-yl) diselenide as orange yellow crystals in 47.8% yield and melting point>300℃。IR (KBr) v: 3036.4 (vAr-H), 1477.5-1566.2 (quinazoline skeleton vibration) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 8.76 (s, 2H, quinazoline H-2), 8.63 (d, J = 2.0 Hz, 2H, quinazoline H-7), 8.20 (d, J = 2.0 Hz, 2H, quinazoline H-5). EIMS: m/z 554 (M+ ·, 24.5)。
Example 8 Synthesis of 1, 2-bis (2-methyl-6-chloroquinazolin-4-yl) diselenide (compound No. i).
Synthesized as in example 1, except for changing 6, 7-dimethoxy-4-chloroquinazoline to 2-methyl-4, 6-dichloroquinazoline, the product 1, 2-bis (2-methyl-6-chloroquinazolin-4-yl) diselenide was obtained as orange red crystals in 43.1% yield and melting point>300℃。IR (KBr) v: 3032.0 (vAr-H), 2974.4 (v as CH3), 2868.2 (v s CH3), 1490.6-1582.0 (quinazoline skeleton vibration) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 8.77 (s, 2H, quinazoline H-2), 8.33 (s, 2H, quinazoline H-5), 7.88 (d, J = 8.8 Hz, 2H, quinazoline H-8), 7.75 (d, J = 8.8 Hz, 2H, quinazoline H-7), 2.49, 2.47 (2s, 6H, 2CH3). EIMS: m/z 512 (M+ ·, 18.3)。
Example 9 Synthesis of 1, 2-bis (2-methyl-6, 8-dichloroquinazolin-4-yl) diselenide (compound No. j).
Synthesized as in example 1, except for changing 6, 7-dimethoxy-4-chloroquinazoline to 2-methyl-4, 6, 8-trichloroquinazoline, the product 1, 2-bis (2-methyl-6, 8-dichloroquinazolin-4-yl) diselenide was obtained as orange red crystals in 40.1% yield and melting point>300℃。IR (KBr) v: 3036.0 (vAr-H), 2971.1 (v as CH3), 2866.7 (v s CH3), 1465.7-1502.6 (quinazoline skeleton vibration) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 8.79 (s, 2H, quinazoline H-2), 8.76 (d, J = 2.0 Hz, 2H, quinazoline H-7), 8.23 (d, J = 2.0 Hz, 2H, quinazoline H-5), 2.44, 2.42 (2s, 6H, 2CH3). EIMS: m/z 582 (M+ ·, 15.4)。
Example 10 synthesis of 1, 2-bis (6-bromoquinazolin-4-yl) diselenide (compound No. m).
Synthesized as in example 1, except for changing 6, 7-dimethoxy-4-chloroquinazoline to 6-bromo-4-chloroquinazoline, the product 1, 2-bis (6-bromoquinazolin-4-yl) diselenide was obtained as orange-red crystals with a yield of 47.5% and a melting point of 47.5%>300℃。IR (KBr) v: 3030.8 (vAr-H), 1458.6-1599.1 (quinazoline skeleton vibration) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 8.81 (s, 2H, quinazoline H-2), 8.46 (s, 2H, quinazoline H-5), 7.92 (d, J = 8.8 Hz, 2H, quinazoline H-8), 7.84 (d, J = 8.8 Hz, 2H, quinazoline H-7). EIMS: m/z 576 (M+ ·, 21.6)。
Example 11 synthesis of 1, 2-bis (6, 8-dibromoquinazolin-4-yl) diselenide (compound No. n).
Synthesized as in example 1, except for changing 6, 7-dimethoxy-4-chloroquinazoline to 6, 8-dibromo-4-chloroquinazoline, the product 1, 2-bis (6, 8-dibromoquinazolin-4-yl) diselenide was obtained as orange-red crystals in 40.7% yield and melting point>300℃。IR (KBr) v: 3030.7 (vAr-H), 1457.7 -1652.6 (quinazoline skeleton vibration) cm-1. 1H NMR (DMSO- 6d, 600 MHz) δ: 8.85 (s, 2H, quinazoline H-2), 8.71 (d, J = 2.0 Hz, 2H, quinazoline H-7), 8.38 (d, J = 2.0 Hz, 2H, quinazoline H-5). EIMS: m/z 732 (M+ ·, 19.2)。
Example 12 Synthesis of 1, 2-bis (6, 7-dimethoxyquinazolin-4-yl) diselenide (compound No. a).
Synthesized as in example 1, except that the solvent absolute ethanol was changed to 50% aqueous ethanol to give the product 1, 2-bis (6, 7-dimethoxyquinazolin-4-yl) diselenide as orange crystals in 38.6% yield and melting point >300 ℃.
Example 13 Synthesis of 1, 2-bis (6, 7-dimethoxyquinazolin-4-yl) diselenide (compound No. a).
Synthesized as in example 1, except that the solvent absolute ethanol was changed toN,NDimethyl formamide, the reaction temperature is maintained in a water bath at 80 ℃, and the product 1, 2-bis (6, 7-dimethoxy quinazoline-4-yl) diselenide is obtained in orange crystal with the yield of 56.1 percent and the melting point>300℃。
Example 14 Synthesis of 1, 2-bis (6, 7-dimethoxyquinazolin-4-yl) diselenide (compound No. a).
Synthesized as in example 1, except that the solvent absolute ethanol was changed to dimethyl sulfoxide and the reaction temperature was maintained in a water bath at 80 ℃ to obtain 1, 2-bis (6, 7-dimethoxyquinazolin-4-yl) diselenide as a product in orange crystals with a yield of 53.7% and a melting point of >300 ℃.
Example 15 proliferation inhibition assay of Compound a on breast cancer cells MDA-MB-435.
The test method comprises the following steps: dissolving the medicine in DMSO to prepare each concentration, and repeating each concentration for three times; MDA-MB-435 cells were digested and made into a suspension of 4X 104Adding 10ml of the powder into a large culture dish, and adding medicine after 24hr of adherence; taking 2 dishes at random after 24hr, and recording cell state; sucking out original culture medium, and processing with medicinal culture medium (10% FBS 1640) for 72 hr; adding 1.5ml pancreatin, digesting for 4min, adding the original drug-containing culture medium to stop digestion, stirring uniformly, counting the number of cells, taking an average value, and calculating the inhibition rate.
And (3) test results: tested, the compoundaThe inhibition rate of the medicament concentration of 10mmol/L on MDA-MB-435 cell proliferation reaches 99.69 +/-0.18%, the effect is much better than that of oxaliplatin which is a positive control medicament, and the medicament shows extremely high anticancer activity.
Example 16, measurement of proliferation inhibition of Breast cancer cell MDA-MB-435 by Compound h.
The test method was the same as in example 15.
And (3) test results: tested, the compoundhThe inhibition rate of the medicament concentration of 10mmol/L on MDA-MB-435 cell proliferation reaches 59.07 +/-3.95%, and the medicament has better effect than a positive control medicament oxaliplatin and shows higher anticancer activity.
Claims (11)
1. An antitumor agent characterized by being a compound represented by the following general formula (I):
(I)
wherein,
R1is hydrogen, R2、R3、R4And R5Each is hydrogen, halogen atom, C1-6 alkyl, C1-6An alkoxy group; but does not include R1、R2、R3、R4And R5Are all hydrogen.
2. The antitumor drug according to claim 1, wherein R in the general formula (I) of the compound is1、R4And R5Are each hydrogen, R2And R3Selected from C1-6 alkyl and C1-6 alkoxy.
3. The antitumor drug according to claim 1, wherein R in the general formula (I) of the compound is1、R3And R5Are each hydrogen, R2And R4Selected from halogen atoms.
4. The antitumor agent according to claim 1, wherein R5 is methyl group and R is represented by the general formula (I)2、R3And R4Selected from halogen atom, C1-6 alkyl, C1-6 alkoxy.
5. The antitumor agent according to claim 2, wherein R is represented by the general formula (I)2And R3Selected from methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, isopentoxy, tert-pentoxy, neopentoxy.
6. The antitumor agent according to claim 3, wherein R is represented by the general formula (I)2And R4Selected from fluorine, chlorine, bromine, iodine atoms.
7. The antitumor agent according to claim 4, wherein R is represented by the general formula (I)2And R3Selected from methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, isopentoxy, tert-butoxyPentoxy, neopentoxy.
8. A medicament according to claim 1 for use against tumors, characterized in that the partially synthesized compound is as follows:
1, 2-bis (6, 7-dimethoxyquinazolin-4-yl) diselenide,
1, 2-bis (6, 7-diethoxyquinazolin-4-yl) diselenide,
c.1, 2-bis (2-methyl-6, 7-dimethoxyquinazolin-4-yl) diselenide,
1, 2-bis (2-methyl-6, 7-diethoxyquinazolin-4-yl) diselenide,
e.g. 1, 2-bis (2-chloro-6, 7-dimethoxyquinazolin-4-yl) diselenide,
f.1, 2-bis (2-chloro-6, 7-diethoxyquinazolin-4-yl) diselenide,
g of 1, 2-bis (6-chloroquinazolin-4-yl) diselenide,
h.1, 2-bis (6, 8-dichloroquinazolin-4-yl) diselenide,
1, 2-bis (2-methyl-6-chloroquinazolin-4-yl) diselenide,
j.1, 2-bis (2-methyl-6, 8-dichloroquinazolin-4-yl) diselenide,
k.1, 2-bis (2, 6-dichloroquinazolin-4-yl) diselenide,
l.1, 2-bis (2,6, 8-trichloroquinazolin-4-yl) diselenide,
m.1, 2-bis (6-bromoquinazolin-4-yl) diselenide,
n.1, 2-bis (6, 8-dibromoquinazolin-4-yl) diselenide,
o.1, 2-bis (2-methyl-6-bromoquinazolin-4-yl) diselenide,
p.1, 2-bis (2-methyl-6, 8-dibromoquinazolin-4-yl) diselenide,
q.1, 2-bis (2-chloro-6-bromoquinazolin-4-yl) diselenide,
r.1, 2-bis (2-chloro-6, 8-dibromoquinazolin-4-yl) diselenide.
9. The preparation method of an antitumor drug according to claim 1, characterized in that the compound is synthesized by using substituted 4-chloroquinazoline, sodium diselenide, potassium diselenide or lithium diselenide as a raw material and water, ethanol, isopropanol, N-dimethylformamide, dioxane, dimethylsulfoxide or a mixture thereof as a solvent: adding substituted 4-chloroquinazoline in batches at the temperature of 20-120 ℃ into the prepared solution of sodium diselenide, potassium diselenide or lithium diselenide, carrying out reflux reaction for 3-36h, cooling, carrying out suction filtration to obtain a brownish red solid, and recrystallizing with N, N-dimethylformamide and water to obtain an orange-to-brownish red crystal, namely the product.
10. Use of the antitumor agent for treating and preventing various benign or malignant tumors according to claim 1.
11. A pharmaceutical composition comprising an effective amount of a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210086997.8A CN102627614B (en) | 2012-03-29 | 2012-03-29 | Diquinazoline diselenide compound as well as preparation method and bioactivity thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210086997.8A CN102627614B (en) | 2012-03-29 | 2012-03-29 | Diquinazoline diselenide compound as well as preparation method and bioactivity thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102627614A CN102627614A (en) | 2012-08-08 |
CN102627614B true CN102627614B (en) | 2014-06-25 |
Family
ID=46586036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210086997.8A Expired - Fee Related CN102627614B (en) | 2012-03-29 | 2012-03-29 | Diquinazoline diselenide compound as well as preparation method and bioactivity thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102627614B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103191121B (en) * | 2013-04-22 | 2015-09-23 | 鲁东大学 | Two (quinazoline-4-base) diselenide compound is preparing the purposes in cancer therapy drug |
CN104000828B (en) * | 2014-06-16 | 2016-07-06 | 鲁东大学 | Quinazoline two selenium salt compounds and preparation method and biologically active |
CN104798808B (en) * | 2015-05-06 | 2017-05-10 | 鲁东大学 | Application of 2-quinazoline diselenide derivatives in preparing phytopathogen resisting medicine |
CN111454240B (en) * | 2020-04-30 | 2023-05-16 | 上海爱启医药技术有限公司 | Process for preparing diselenide compounds |
CN113004210A (en) * | 2021-03-29 | 2021-06-22 | 鲁东大学 | Quinazoline-4-selenium salt compound, preparation method and biological activity |
CN113135861B (en) * | 2021-04-30 | 2022-10-11 | 重庆理工大学 | Ligustrazine derivative and preparation method and application thereof |
-
2012
- 2012-03-29 CN CN201210086997.8A patent/CN102627614B/en not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
HARJIT SINGH et al..Synthesis of Functionalised Heterocyclic Selenoamide Derivatives & Their Reactions.《Indian Journal of Chemistry》.1983,第22B卷328-330. |
HARJIT SINGH et al..Synthesis of Functionalised Heterocyclic Selenoamide Derivatives & * |
Pfeiffer, W.-D..Product class 23: annulated selenazole compounds.《Science of Synthesis》.2002,第11卷996. * |
Their Reactions.《Indian Journal of Chemistry》.1983,第22B卷328-330. * |
刘刚等.4-硫醚基喹唑啉类化合物的合成及抑菌活性研究.《有机化学》.2008,第28卷(第3期),525-530. * |
Also Published As
Publication number | Publication date |
---|---|
CN102627614A (en) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102627614B (en) | Diquinazoline diselenide compound as well as preparation method and bioactivity thereof | |
Cao et al. | Synthesis and structure–activity relationships of harmine derivatives as potential antitumor agents | |
JP5719770B2 (en) | Icotinib hydrochloride, compound, crystallographic form, concomitant drug and its use | |
KR101839915B1 (en) | Arylamino purine derivatives, preparation method and pharmaceutical use thereof | |
EP2857393B1 (en) | N-aryl unsaturated fused ring tertiary amine compound, preparation method thereof and antitumor application thereof | |
CN104326979B (en) | 2-methyl-9-acridine (to methoxy benzamide base) thiocarbamide and its production and use | |
CN109293657B (en) | Alpha-carboline ketone compound and preparation method and application thereof | |
CN113061138A (en) | Triazole [5,4-d ] pyrimidone tricyclic compound and preparation method and application thereof | |
CN102887904A (en) | 2,3-dioxyethyl-5-methyl-8,9-dimethoxy benzophenanthridine derivative, and preparation method and application thereof | |
CN115197227A (en) | Tryptanthrin 1-position or 3-position substituted aromatic thioether derivative, and preparation method and application thereof | |
CN104000828B (en) | Quinazoline two selenium salt compounds and preparation method and biologically active | |
CN106045980B (en) | A kind of quinazoline derivant and preparation method thereof | |
CN106892922B (en) | As the 5,8- dihydropteridine -6,7- derovatives of EGFR inhibitor and its application | |
US20230322687A1 (en) | Salt of arylaminoquinazoline-containing compound, and preparation method therefor and use thereof | |
CN103864642B (en) | Rhein derivatives and preparation method and use thereof | |
CN106397407B (en) | The preparation method of antitumor drug AZD9291 derivatives | |
CN102093339B (en) | Preparation method and application of pyrimidine derivatives | |
CN115124531A (en) | 4-azatryptanthrin aromatic thioether derivatives, and preparation method and application thereof | |
CN104945364B (en) | A kind of A Kela determines the purposes of compound and the compound | |
WO2018014368A1 (en) | Water-soluble isatin derivative, and manufacturing method and application thereof | |
CN102229563A (en) | 4-amino quinoline derivative, preparation method and application thereof | |
Mule et al. | Synthesis, biological screening and molecular docking studies of novel 4, 6-pyrimidine derivatives as EGFR-TK inhibitors | |
CN113004210A (en) | Quinazoline-4-selenium salt compound, preparation method and biological activity | |
CN105601685B (en) | The oligosaccharide derivative of toroidal shell containing quinazoline and preparation method and bioactivity | |
CN105520951B (en) | The polysaccharid derivative of toroidal shell containing quinazoline and preparation method and bioactivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140625 Termination date: 20150329 |
|
EXPY | Termination of patent right or utility model |